Both in Pharmaceuticals
PUMA BIOTECHNOLOGY vs Capricor Therapeutics
Over the past year PBYI returned +93.7% and CAPR returned +15.7%; their daily moves had a correlation of 0.10.
PBYI +93.7% CAPR +15.7%Growth of $1, one year, split-adjusted
| Metric | PBYI | CAPR |
|---|---|---|
| Price | $9.78 | $8.57 |
| Market cap | $504.8M | $498.3M |
| Today | −0.41% | −1.61% |
| 1 month | +7.9% | −10.6% |
| 6 months | +59.5% | −69.1% |
| Year to date | +64.4% | −70.3% |
| 1 year | +102.1% | — |
| Revenue growth (YoY) | +7.8% | — |
| Gross margin | 77.9% | — |
| Net margin | 14.5% | — |
| P/E (TTM) | 18.9× | — |
| Price / sales | 2.2× | — |
| Net cash | $93.9M | $237.9M |
| Dividend yield | — | — |
| Volatility (60d) | 43.1% | 265.6% |
| Short % of float | 11.2% | 48.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).